Unified Series Trust OneAscent Core Plus Bond ETF (ARCA: OACP)

Latest news for Unified Series Trust OneAscent Core Plus Bond ETF (ARCA:OACP)

Under normal circumstances, the Fund invests at least 80% of its assets in bonds. For these purposes, bonds include fixed-income securities of all types. The Fund primarily invests in a broad range of investment-grade bonds and fixed-income securities, including, but not limited to, U.S. Government securities, corporate bonds, taxable municipal securities and mortgage-backed or other asset-backed securities. The Fund may also invest in other fixed-income securities, including those of non-investment- grade quality (usually called high-yield or junk bonds). Securities of non-investment-grade quality are speculative in nature. The Fund may invest in fixed-income securities of any duration. For purposes of the 80% investment policy, the term assets means net assets, plus the amount of any borrowings for investment purposes.

OneAscent Core Plus Bond ETF

Unified Series Trust OneAscent Core Plus Bond ETF

Maxim Group analyst Michael Okunewitch maintains Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and lowers the price target from $15 to $6.

News

Price Target

Analyst Ratings

LGVN

Maxim Group Maintains Buy on Longeveron, Lowers Price Target to $6

RBC Capital analyst Nik Modi reiterates Campbell Soup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Sector Perform and maintains $47 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Campbell Soup, Maintains $47 Price Target

<a href="https://www.reuters.com/legal/government/nfl-players-union-sues-draftkings-allegedly-breaking-nft-contract-2024-08-26/" title="https://www.reuters.com/legal/government/nfl-players-union-sues-draftkings-allegedly-breaking-nft-contract-2024-08-26/">https://www.reuters.com/legal/government/nfl-players-union-sues-draftkings-allegedly-breaking-nft-contract-2024-08-26/</a>

DKNG

Reported August 26: NFL Players Association Sues DraftKings In New York Federal Court, Accusing The Company Of Breaching Licensing Agreement Over NFL Player NFTs After Shuttering Its NFT Business; DraftKings Declines To Comment On The Lawsuit

Trading Ideas

JBDI

JBDI Shares Halted On Circuit Breaker To The Upside

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and maintains $200 price target.

Stifel Maintains Buy on Zoetis, Maintains $200 Price Target

Ross Gerber, the co-founder and CEO of Gerber Kawasaki Wealth and Investment Management, is known for his influence in the world of finance. However, his connection to the cannabis industry dates back much further than his investment endeavors. Gerber's entry into the cannabis space started during his college days when a chance meeting with an activist inspired him to take up <a href="https://www.benzinga.com/topic/cannabis-legalization">the cause of legalization</a>.
<h3 class="wp-block-heading">A Rally That Sparked a Passion</h3>
Gerber's involvement in the cannabis movement began in the early 1990s while he was attending the University of Pennsylvania. He recalls meeting Jack Herer, a legendary cannabis activist, and being inspired to advocate for legalization. 
"I met this guy named Jack Herer who was running this thing called NORML, and he was this crazy guy," Gerber shared. "Honestly, I smoked a jay with him in Venice Beach, and I was a kid, and he kind of inspired me to, like, take up this idea of legalization."
This encounter led Gerber to organize a cannabis legalization rally on campus, which turned out to be a pivotal moment for him. "We followed all the rules and applied for the permits, and did everything. And the day came, and sure enough, six trucks full of hippies and Jack Herer show up for this thing right in the middle of campus," he said. The rally, which drew around 5,000 people, became the largest cannabis legalization rally in the history of the University of Pennsylvania, says Gerber.
<h3 class="wp-block-heading">A Lifelong Advocate for Cannabis Legalization</h3>
Gerber's belief in the absurdity of cannabis prohibition has remained a constant throughout his life. Over the years, he continued to view cannabis not just as a recreational substance but as a medicine that helped him with sleep and stress. "I've more than determined that cannabis is medicine, and it's not extremely strong medicine, but it definitely works for things like stress and sleep," he noted.
His early experiences with the cannabis movement eventually dovetailed with his career in finance. As the cannabis industry moved toward legalization, Gerber saw an opportunity to not only support the movement but also invest in it. His personal beliefs and professional interests aligned, leading him to become a vocal advocate for cannabis reform and a key investor in the industry.
<h3 class="wp-block-heading">Advocating for Change at the Benzinga Cannabis Capital Conference</h3>
Gerber's journey from college activist to cannabis investor will be one of the topics he addresses at the upcoming Benzinga Cannabis Capital Conference in Chicago, October 8-9, 2024. As an industry advocate, Gerber will continue to push for federal reform and encourage others to recognize the potential of cannabis as both a medicine and an economic opportunity.
For Gerber, the fight for cannabis legalization is not just a business endeavor — it's a deeply personal mission that began with a simple rally on a college campus and has grown into a lifelong commitment to change.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40565943/ron-desantis-anti-cannabis-warpath-strewn-with-dissenting-gop-colleagues-not-enough-money-polls-">Ron DeSantis&#8217; Anti-Cannabis Warpath Strewn With Dissenting GOP Colleagues, Not Enough Money, Polls Favoring Legalization</a></li>
</ul>

Cannabis

Events

Exclusives

Interview

From A College Cannabis Rally To A Major Industry Advocate: Ross Gerber's Journey Into Cannabis

IPOs

JBDI Holdings Shares Open For Trade At $5/Share; IPO Priced At $5/Share On 2.25M Shares

In his interview with prominent podcast host Joe Rogan, venture capitalist and businessman Peter Thiel offered a stark comparison between the <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40434156/peter-thiel-calls-bitcoin-moderately-big-invention-compared-with-the-internet-it-was-syste">cryptocurrency and artificial intelligence</a> (AI) industries. Thiel suggested that while crypto embraced decentralization, AI is poised to become a highly centralized technology.
What Happened: Known for his insightful tech industry predictions, the billionaire <a href="https://x.com/tsarnick/status/1824566247960482283">posited</a> that &#8220;if we say crypto is libertarian, can we also say AI is communist?&#8221; 
The tech mogul highlighted that cryptocurrency&#8217;s appeal lay in its ability to operate outside traditional financial hubs, with companies and protocols able to function from locations like <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21735896/bitcoin-2021-miamis-crypto-movement-the-rise-of-digital-assets">Miami</a>.
However, Thiel argues that AI presents a completely different scenario, with the technology naturally gravitating towards big tech companies in <a href="https://www.benzinga.com/news/24/08/40543516/silicon-valley-gets-political-as-presidential-election-nears">Silicon Valley</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40573220/coinbase-leads-the-blockchain-industrys-unprecedented-donation-spree-in-2024-election">Coinbase Leads The Blockchain Industry&#8217;s Unprecedented Donation Spree In 2024 Election</a>
&#8220;The natural structure for an AI company looks like it&#8217;s a big company,&#8221; Thiel stated, adding that &#8220;AI stuff feels like it&#8217;s going to be dominated by the big tech companies in the San Francisco Bay area.&#8221; 
He emphasized that the scale of the AI industry makes it &#8220;extremely hard to get out of the San Francisco Bay area,&#8221; suggesting a concentration of power and resources in the hands of a few large corporations.
This perspective offers a compelling counterpoint to the decentralized vision often associated with blockchain technology and cryptocurrencies. 
What&#8217;s Next: As the tech landscape continues to evolve, Thiel&#8217;s insights raise important questions about the future of digital technologies and their impact on global power structures.
For those interested in exploring these themes further, Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on November 19 promises to delve deeper into the intersection of cryptocurrencies, AI and the broader digital asset ecosystem.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40572558/bitcoin-etfs-surge-past-18b-in-net-inflows-ethereum-etfs-have-bled-478m-what-is-going-on">Bitcoin ETFs Surge Past $18B In Net Inflows, Ethereum ETFs Have Bled $478M: What Is Going On?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Peter Thiel's Tech Prophecy: If We Say 'Crypto Is Libertarian,' Can We Also Say 'AI Is Communist'?

Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:
<h3>SPDR S&amp;P 500 ETF Trust</h3>
SPY&nbsp;is currently trading around our key level of 560.83. For the bulls, a move above 561.90 would be a strong signal of upward momentum. If this level is held, we anticipate the price to target 563.23 as a solid support area. Sustained bullish activity could push SPY further to 564.29. Our high bull target for the day is positioned at 565.38, which could be reached if the buying momentum continues throughout the session.
On the flip side, if 560.83 fails to hold as support, we expect the bears to challenge 559.75. A break below this level could see the price testing 558.32. If selling pressure persists, a move down to 557.44 could be on the cards. In a scenario of heavy selling, our low bear target for SPY is set at 556.27.
<h3>Invesco QQQ Trust Series 1</h3>
QQQ&nbsp;is currently trading near our critical level of 474.66. For the bulls, strength above 476.85 would indicate a positive start, with 479.03 as the next key support level. Should this level hold, we could see the price advance to 481.73. If the bulls maintain control, a higher move towards 483.95 is possible, with our high bull target on the day being 486.10.
However, if the auction struggles to hold 474.66, we expect the bears to take over and push the price down to 471.33. If this level is breached, a further decline to 469.27 could follow. Continued bearish momentum might lead to a test of 467.60. Should the sell-off intensify, our low bear target for QQQ is 465.93.
<h3>Apple Inc.</h3>
Apple&nbsp;is currently hovering around our key level of 226.90. Bulls will want to see this level hold as support, with an initial target of 227.82 on the upside. If buying pressure sustains, a further push towards 229.03 could be in play. Should the bulls retain control, the price might rally to our high bull target for the day at 230.25.
If 226.90 fails to act as support, we could see a move down to 226.08. Bears might then test 225.31, with continued downside pressure bringing 223.87 into focus. If the selling persists, the low bear target for Apple today is positioned at 222.96.
<h3>Microsoft Corp.</h3>
Microsoft&nbsp;is currently trading around 413.14. Bulls will be looking to hold this level as support, aiming for an initial rally towards 414.56. Should this level be secured, further upside could lead the price to 416.32. If buying momentum continues, the high bull target on the day for Microsoft is set at 417.25.
Conversely, if 413.14 fails to hold as support, bears are likely to target 411.72. A break below this level could see the price declining to 410.64. If selling pressure continues, a move down to 409.69 is possible, with our low bear target for Microsoft at 408.46.
<h3>NVIDIA Corporation</h3>
NVIDIA&nbsp;is currently trading near our key level of 126.84. For the bulls, a move higher to 128.10 would be a strong start, with this level acting as support if maintained. Continued bullish momentum could drive the price to 129.53. Should the uptrend persist, a rally towards our high bull target of 132.19 could unfold.
If 126.84 fails as support, we anticipate a test lower at 125.21. A break below this level could see the price drop to 123.41. If selling continues, a further decline to 121.97 is expected. Our low bear target for NVIDIA today is positioned at 120.27, in the case of a more pronounced sell-off.
<h3>Alphabet Inc Class A</h3>
Alphabet&nbsp;is currently trading around our key level of 165.41. Bulls will want to see this level hold as support, aiming for a push towards 167.04. If buying pressure sustains, we could see a move higher to 169.34. Should the bulls maintain control, this could be our high bull target for the day.
If 165.41 fails to hold as support, we anticipate a move down to 163.79. If this level is breached, a further decline to 161.79 could follow. On continued bearish momentum, we expect the price to test our low bear target for Alphabet at 160.36.
<h3>Meta Platforms Inc</h3>
Meta&nbsp;is currently auctioning near our level of 520.27. Bulls will be watching this level to hold as support, with an initial upside target of 526.29. Should buying strength continue, the price could advance to 531.03. If bullish momentum persists, the high bull target for Meta today is set at 534.33.
On the downside, if 520.27 fails to act as support, bears are likely to push the price lower to 515.39. Continued selling could see the price testing 512.85, with further downside likely leading to a low bear target of 508.25.
<h3>Tesla Inc. </h3>
Tesla&nbsp;is currently trading around 213.88, a key level to watch. Bulls will aim for a push towards 216.31, with 217.78 as the next upside target if buying momentum holds. Should the bulls take charge, a move to 219.39 is possible, with the high bull target on the day being 220.65.
If 213.88 doesn&#39;t hold as support, we expect the bears to drive the price down to 211.53. Continued selling pressure could lead to a test of 209.51. If this level is broken, our low bear target for Tesla today is positioned at 206.71.
Final Word: Today&rsquo;s trading session is packed with critical data releases that could have a significant impact on market movements. The first release comes at 9 AM ET with the House Price Purchase Index for June and the FHFA House Price Index, which provide insights into housing market trends. At 10 AM ET, the Conference Board Consumer Confidence reading for August will be released, a key indicator likely to set the tone for the market. This is followed by the Dallas Fed Services Activity report at 10:30 AM ET, offering a view into the service sector&rsquo;s performance.
As the session progresses, attention will turn to the 2-Year Note Auction at 1 PM ET, a crucial event for gauging investor sentiment regarding short-term debt instruments. The day concludes with the release of the Fed&#39;s Discount Rate Minutes at 2 PM ET, which could provide insights into the central bank&#39;s recent discussions and future monetary policy directions. Given the breadth of significant data points, today promises to be a highly volatile session. Traders should stay alert and manage their risk carefully, as rapid market movements could occur. Good luck, keep your head on a swivel, and trade safely!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Markets

General

Market Clubhouse Morning Memo - August 27th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)

Stifel analyst Matthew Smith maintains Campbell Soup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Hold and maintains $45 price target.

Stifel Maintains Hold on Campbell Soup, Maintains $45 Price Target

Barclays analyst Tim Long maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Underweight and lowers the price target from $108 to $104.

Barclays Maintains Underweight on Ubiquiti, Lowers Price Target to $104

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Equal-Weight and raises the price target from $144 to $154.

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $154

Barclays analyst Jiong Shao maintains PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) with a Overweight and lowers the price target from $224 to $158.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Barclays Maintains Overweight on PDD Holdings, Lowers Price Target to $158

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $33 price target.

Truist Securities Maintains Buy on Evolent Health, Maintains $33 Price Target

Commercial and multifamily loan originations skyrocketed 27% from the year&#8217;s first quarter. They ticked up 3% compared to a year ago, according to the Mortgage Bankers Association's (MBA) second-quarter survey.
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
"Borrowing and lending backed by <a href="https://www.benzinga.com/real-estate/24/05/38586435/commercial-foreclosures-spike-by-nearly-120-in-the-last-12-months">commercial real estate</a> remained subdued in the second quarter," said Jamie Woodwell, MBA's head of commercial real estate research. "Most capital sources remain ready, willing and able to lend on properties that can support a loan. Driven by growth in the single-asset single-borrower markets, originations for CMBS [commercial mortgage-backed securities] grew significantly during the quarter."
The second quarter of 2024 saw a significant increase in <a href="https://www.benzinga.com/real-estate/24/06/39550000/why-this-economist-thinks-a-major-commercial-real-estate-crash-could-take-down-the-fdic">commercial loan originations</a>, with several property types experiencing substantial growth. Health care properties led the surge with a 178% increase from the previous quarter. Hotels followed closely with an 84% rise, while industrial properties saw a 29% increase and multifamily properties experienced a 27% uptick. Retail properties also recorded an 18% increase, while office properties saw a more modest 4% growth in loan dollar volume.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Investor types also played a significant role in the increased originations. Life insurance companies saw a substantial 60% increase in loan dollar volume from the first to the second quarter. Depositories and CMBS experienced 21% increases, while investor-driven lenders saw a 20% rise. Government-sponsored enterprises (GSEs) also contributed to the growth with a 16% increase in loan dollar volume.
While several commercial property types saw significant year-over-year increases in mortgage loan originations during the second quarter, others experienced declines. Hotels led the surge with a 172% increase, followed by industrial properties at 77% and health care properties at 50%. However, retail properties saw a 7% decline, multifamily properties decreased by 14% and office properties experienced a more substantial 29% drop.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Among investor types, CMBS saw a dramatic 154% increase in loan dollar volume year over year. Investor-driven lenders also experienced growth, with a 17% increase. Life insurance companies saw a more modest 11% rise. Conversely, depositories and GSEs faced declines, dropping by 26% and GSEs by 20%.
"With interest rates moderating and a large slug of loans maturing, it is likely we'll see more borrower activity in the coming quarters," Woodwell said.&nbsp;
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>Elon Musk&#8217;s secret mansion in Austin revealed through court filings.<a href="https://www.benzinga.com/money/elon-musk-secret-mansion-austin-nada"> Here&#8217;s how to invest in the city&#8217;s growth before prices go back up.</a></li>
</ul>

Real Estate

Commercial And Multifamily Mortgage Originations Surge 27% In Q2

One of the most famous sports-based podcasts has found a new home with "New Heights" landing a $100 million deal with Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Wondery, bringing the Kelce brothers further into the NFL ecosystem <a href="https://www.benzinga.com/news/23/10/35146521/amazon-is-winning-its-bet-on-nfl-rights-a-look-at-the-numbers-taylor-swift-upside">of the ecommerce giant.</a>
What Happened: Launched in 2022, "New Heights" comes from brothers Jason Kelce and Travis Kelce. While Jason retired from the NFL after a 13-year career, Travis is crucial to the Kansas City Chiefs&#8217; pursuit of a historic <a href="https://www.benzinga.com/general/sports-betting/24/07/39752864/bettors-favor-kansas-city-chiefs-for-super-bowl-three-peat-heres-a-look-at-how-states-are-">Super Bowl three-peat</a> in the 2024 season.
Amazon's Wondery landed the rights to ad-sales, distribution and more across a three-year $100 million deal, as reported by <a href="https://variety.com/2024/digital/news/kelce-brothers-podcast-wondery-new-heights-1236118594/">Variety</a>. Wondery will also have rights to the back catalog of episodes and the rights to create international audio versions of the podcast. Wondery also gains rights to develop and license merchandise based on the hit podcast.
The deal with the weekly podcast kicks off Wednesday Aug. 28 ahead of the 2024 NFL season. The podcast features a look at the day-to-day lives of the brothers, along with their NFL careers and special guests talking football, sports and various other topics. "New Heights" ranks among the most popular podcasts on Spotify and Apple Podcast. The podcast was named 2024 Podcast of the Year at the iHeartPodcast Awards.
Wondery+ subscribers can enjoy ad-free listening of &#8220;New Heights,&#8221; which will also be available across Wondery's distribution network and on YouTube.
"We couldn't be more excited to team up with Wondery for the next phase of ‘New Heights," the Kelce brothers said in a statement. "We love this show, and the fanbase that has grown with us over the last two seasons."
The Kelce brothers said Wondery brings experience and resources to take the podcast to "new heights," in a pun on the show's title.
Wondery CEO Jen Sargent said the Amazon owned company has been following the podcast over the last two years.
"'New Heights' on the surface is a sports podcast, and sports is such a well-listened to category," Sargent said. "But it's become a cultural phenomenon – they're in that cultural zeitgeist."
While "New Heights" was already popular with NFL and sports fans, the podcast may have also gotten a viewership boost with increased interest in Travis' personal life thanks to his relationship with global superstar Taylor Swift.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/03/37872731/will-travis-kelce-be-able-to-balance-nfl-career-taylor-swift-romance-and-an-amazon-prime-sh">Will Travis Kelce Be Able To Balance NFL Career, Taylor Swift Romance, And An Amazon Prime Show Hosting Gig?</a>
Why It's Important: Neither Kelce brother is a stranger to Amazon and the ecommerce company's growing bets on the NFL and sports.
Jason was featured in a 2023 documentary "Kelce" in 2023 that became Prime Video's <a href="https://www.benzinga.com/general/entertainment/23/10/35203931/beckham-scores-for-netflix-kelce-for-amazon-messi-up-next-for-apple-sports-documentaries-hi">most watched documentary </a>of all time. Travis landed a deal with Amazon's Prime Video for a<a href="https://www.benzinga.com/general/entertainment/24/05/38860861/amazon-betting-on-game-shows-for-streaming-growth-mrbeast-travis-kelce-pop-culture-jeopardy"> new version of the game show</a> "Are You Smarter Than a 5th Grader" with the upcoming "Are You Smarter Than a Celebrity?"
Amazon also <a href="https://www.benzinga.com/topic/thursday-night-football">has the rights</a> to NFL "Thursday Night Football" games, which have attracted strong viewership and helped the company boost Prime Video subscribers.
While Travis returns to the field for a 12th NFL season, Jason turns to a commentator position for ESPN's "Monday Night Countdown" pregame show alongside his weekly podcast.
The $100 million podcast deal follows several other large deals announced in the sector. Wondery signed an $80 million deal with actor Dax Shepard last month.
SiriusXM recently announced a<a href="https://www.benzinga.com/news/24/08/40472192/why-are-sirius-xm-shares-on-the-rise-today"> $125 million podcast deal </a>with Alex Cooper for "Call Her Daddy." Joe Rogan <a href="https://www.benzinga.com/markets/equities/24/02/36914209/spotify-inks-multiyear-deal-with-podcast-king-joe-rogan-amid-shifting-strategy">landed a $250 million </a>multiyear deal to stay with Spotify earlier this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/05/38909548/2024-nfl-schedule-unpacked-media-partners-win-taylor-swift-tour-dates-considered-new-betti">2024 NFL Schedule Unpacked: Media Partners Win, Taylor Swift Tour Dates Considered, New Betting Odds And More</a></li>
</ul>
Photo: Featureflash Photo Agency/Shutterstock.com

Entertainment

Sports

AMZN

Travis Kelce, Jason Kelce Sign $100M Podcast Deal With Amazon: Ecommerce Giant Bets Big On NFL, Brothers' Success

Partnership Aims to Increase Satisfaction, Loyalty, and Retention Rates of Pluxee Cardholders
São Paulo, August 27, 2024 – DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>), a leading Fortune 500 global IT services provider, announced today that it will collaborate with Pluxee, a major global partner for employee benefits and engagement, inheriting the legacy of Sodexo Benefits and Rewards, to process benefit card transactions for the company's 7.1 million users in Brazil."
Pluxee Card helps create&nbsp;opportunities for business&nbsp;by linking recognition, incentive, and employee benefits strategies into one digital payment mechanism. The company handles up to 400 transactions per second between cardholders and commercial entities, enabled by transaction speed and service reliability.&nbsp;
DXC will provide secure and agile processing of contactless card activities, one of Pluxee's digital benefits, which offers cashback on purchases made with the cards to enhance user satisfaction, loyalty, and retention.&nbsp;

Global

DXC Technology And Pluxee To Optimize Transaction Processing And Benefits For 7.1M Users In Brazil

Visa Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares are trading marginally higher on Tuesday. The company launched its Money Movement Advisory Practice in the U.S. and Canada through <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40571981/visa-launches-money-movement-advisory-practice-in-north-america" rel="noreferrer noopener">Visa Consulting &amp; Analytics (VCA)</a>.
This new service aims to assist clients and partners in navigating the complex money movement industry and seizing opportunities within the estimated $200 trillion global market.
Visa&#8217;s Money Movement Advisory Practice addresses the growing demand for seamless payments and mobile experiences.
Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40111848/mastercard-outperforms-visa-in-q2-analysts-highlight-defensive-edge-in-spending-vol" rel="noreferrer noopener">Mastercard Outperforms Visa In Q2; Analysts Highlight Defensive Edge In Spending Volatility</a>
It focuses on &#8216;Money Movement,&#8217; which includes various methods for transferring funds across platforms.
These services connect clients to up to 8.5 billion endpoints in over 190 countries and territories across 160 currencies, advancing a more innovative financial ecosystem.
VCA Implementation Support and Services will also play a crucial role in enabling clients to effectively utilize Visa&#8217;s Money Movement solutions, accelerating product integration, time to market, and adoption.
Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39937524/visa-faces-continued-softer-macro-trends-these-7-analysts-dive-into-q3-results" rel="noreferrer noopener">Visa Faces Continued Softer Macro Trends: These 7 Analysts Dive Into Q3 Results</a>
Kate Manfred, North America Head of Advisory Services at Visa, said, &#8220;Clients are actively seeking effective strategies to meet the increasing customer demand for quick, reliable payments.&#8221;
&#8220;Visa can be their strategic partner, offering innovative solutions for money movement that will drive new sources of growth and customer retention.&#8221;
Investors can gain access to the stock via iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and SPDR Select Sector Fund &#8211; Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>).
Price Action: V shares are up 0.25% at $268.87 at the last check Tuesday.
Image from Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40576505" target="_blank" rel="noreferrer noopener">Nvidia Stock&#8217;s Technical Indicators Show Bullish Momentum Ahead Of Q2 Earnings</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Large Cap

iShares Trust Dow Jones US Financial Services Index Fund

What's Going On With Visa Stock Tuesday?

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Editor&#8217;s Note: The story has been updated with the Phase 3 trial data in Japan and neffy&#8217;s pricing information.
Earlier this month, the FDA approved ARS Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for <a href="https://www.benzinga.com/news/24/08/40467939/ars-pharmaceuticals-neffy-uniquely-positioned-with-potential-to-change-allergy-treatment-paradigm-fo" target="_blank" rel="noreferrer noopener">adult and pediatric patients</a>.
The nasal spray version of epinephrine is poised to enter the market as an alternative to auto-injectors like the EpiPen for treating severe allergic reactions.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37221031/ars-pharma-readies-data-in-response-to-fdas-rejection-for-its-epipen-alternative-fo" rel="noreferrer noopener">ARS Pharma Readies Data In Response To FDA&#8217;s Rejection For Its EpiPen Alternative For Severe Allergic Reactions</a>.
While Neffy&#8217;s needle-free application offers a more convenient and potentially less painful option, some allergists are hesitant to prescribe it until further studies confirm its effectiveness during actual anaphylactic emergencies.
The company <a href="https://ir.ars-pharma.com/static-files/aba6460e-af90-4a1a-a0e0-e0407eacd111" target="_blank" rel="noreferrer noopener">conducted</a> a Phase 3 study in Japanese pediatric patients (n=15) who experienced food allergies. Data showed that no patient needed a second dose of epinephrine within 15 minutes post-dose, and neffy provided similar efficacy to existing epinephrine therapies. Most patients experience significant symptom relief within five minutes of administration.
According to a pediatric allergist at UT Southwestern and director of the Food Allergy Center at Children&#8217;s Medical Center in Dallas, Neffy could be particularly beneficial for adults hesitant to self-inject and parents uneasy about injecting their children.
Neffy&#8217;s small size—roughly half the size of an iPhone—also makes it easier to carry, potentially boosting compliance among high-risk patients.
A 2023 study found that only about 40% of those at high risk consistently carry their auto-injectors, citing inconvenience and a false sense of security as primary reasons.
The NPR report <a target="_blank" href="https://www.benzinga.com/news/24/08/40467939/ars-pharmaceuticals-neffy-uniquely-positioned-with-potential-to-change-allergy-treatment-paradigm-fo" rel="noreferrer noopener">adds</a> that ARS Pharmaceuticals took over eight years to develop Neffy. It offers several advantages over auto-injectors like the EpiPen.
Its shelf life extends to two years, compared to the typical 12-18 months for auto-injectors, and it can withstand temperature fluctuations, unlike EpiPens, which must be stored at room temperature.
The report notes that Neffy could become the preferred option in public settings like schools and airplanes due to its ease of storage and use.
However, some physicians remain cautious, as they highlight that Neffy has not been tested in patients experiencing real-time anaphylactic reactions, raising concerns about its efficacy.
Nasal congestion during an allergic reaction could block the drug&#8217;s absorption, potentially worsening the reaction.
Insurance coverage is another uncertainty. ARS is working with insurers to get Neffy approved, a process that could take up to six months.
Since Mylan acquired U.S. rights to the EpiPen in 2007, its price has come under scrutiny due to a 600% increase, now retailing between $650 and $750 without insurance. The generic version ranges from $150 to $200 per GoodRx data. 
ARS Pharma announced that most patients with commercial insurance covering Neffy can pay $25 for two single-use devices through a <a href="https://www.benzinga.com/pressreleases/24/08/g40290428/ars-pharmaceuticals-receives-fda-approval-of-neffy-epinephrine-nasal-spray-the-first-and-only-need" target="_blank" rel="noreferrer noopener">co-pay savings program</a>. 
For uninsured patients, those with plans not covering Neffy or those with high out-of-pocket costs, ARS Pharma offers a $199 cash price for two doses via BlinkRx, also available through GoodRx. Additionally, eligible uninsured or underinsured individuals in the U.S. can access Neffy for free through ARS Pharma&#8217;s Patient Assistance Program.
Despite these developments, some doctors plan to delay prescribing Neffy initially, citing the administrative burden of navigating insurance coverage for a new drug.
Price Action: SPRY stock is up 1.92% at $13.45 at the last check on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40528681/intel-board-member-lip-bu-tan-resigns-amid-chipmakers-struggle-with-cost-cuts" target="_blank" rel="noreferrer noopener">Intel Board Member Lip-Bu Tan Resigns Amid Chipmaker&#8217;s Struggle With Cost Cuts</a>.</li>
</ul>
Photo via ARS Pharmaceuticals

Biotech

Health Care

SPRY

Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Comments

Unified Series Trust OneAscent Core Plus Bond ETF

News

Latest news for Unified Series Trust OneAscent Core Plus Bond ETF (ARCA:OACP)